Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 9/20 | 0.57 |
| ▸ | PTGER2 | P43116 | 9/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | PTGER3 | P43115 | 9/20 | 0.54 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | EPOR | P19235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7955611 | 1.00 | PTGER4 (0.57) | PTGER4PTGER2FFAR1PTGER3PTGER1 | |
| SCHEMBL7959169 | 0.90 | PTGER4 (0.49) | PTGER4PTGER2FFAR1PTGER3PTGER1 | |
| SCHEMBL27691613 | 0.86 | FFAR1 (0.55) | FFAR1LMNAP2RX3KDM4EALDH1A1 | |
| SCHEMBL7809016 | 0.80 | PTGER4 (0.70) | PTGER4PTGER2FFAR1PTGER3PTGER1 | |
| SCHEMBL7809010 | 0.80 | PTGER4 (0.70) | PTGER4PTGER2FFAR1PTGER3PTGER1 | |
| SCHEMBL7955803 | 0.79 | FFAR1 (0.52) | PTGER4PTGER2FFAR1PTGER3PTGER1 | |
| SCHEMBL7955806 | 0.79 | FFAR1 (0.52) | PTGER4PTGER2FFAR1PTGER3PTGER1 | |
| SCHEMBL7798335 | 0.79 | PTGER4 (0.71) | PTGER4PTGER2PTGER3PTGER1HTT | |
| SCHEMBL7798329 | 0.79 | PTGER4 (0.71) | PTGER4PTGER2PTGER3PTGER1HTT | |
| SCHEMBL10446475 | 0.74 | ALDH1A1 (0.50) | FFAR1HTTKDM4EALDH1A1EPOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031766-A1 | Prostaglandin receptor ligands | MERCK FROSST CANADA & CO. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031766-A1 | Prostaglandin receptor ligands | PTGER1, PTGER2, PTGFR | PTGER4 11/4885PTGER2 2/4885FFAR1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.